Johnson & Johnson (JNJ) : Hendley Co Inc reduced its stake in Johnson & Johnson by 0.24% during the most recent quarter end. The investment management company now holds a total of 50,849 shares of Johnson & Johnson which is valued at $5,762,209 after selling 121 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.Johnson & Johnson makes up approximately 3.52% of Hendley Co Inc’s portfolio.
Johnson & Johnson closed down -0.14 points or -0.12% at $112.77 with 57,59,301 shares getting traded on Wednesday. Post opening the session at $112.96, the shares hit an intraday low of $112.46 and an intraday high of $113.2 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , Headinvest boosted its stake in JNJ in the latest quarter, The investment management firm added 650 additional shares and now holds a total of 18,951 shares of Johnson & Johnson which is valued at $2,147,527. Johnson & Johnson makes up approx 0.83% of Headinvest’s portfolio.Osborn Rohs Williams Donohoe Ltd reduced its stake in JNJ by selling 1,611 shares or 1.62% in the most recent quarter. The Hedge Fund company now holds 97,881 shares of JNJ which is valued at $10,784,529. Johnson & Johnson makes up approx 2.14% of Osborn Rohs Williams Donohoe Ltd’s portfolio. Maple Securities Usa Inc sold out all of its stake in JNJ during the most recent quarter. The investment firm sold 37,104 shares of JNJ which is valued $4,088,119. Daiwa Sb Investments Ltd. added JNJ to its portfolio by purchasing 2,740 company shares during the most recent quarter which is valued at $301,893. Johnson & Johnson makes up approx 0.08% of Daiwa Sb Investments Ltd.’s portfolio.Abner Herrman Brock boosted its stake in JNJ in the latest quarter, The investment management firm added 5,740 additional shares and now holds a total of 9,469 shares of Johnson & Johnson which is valued at $1,031,837. Johnson & Johnson makes up approx 0.26% of Abner Herrman Brock’s portfolio.
On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $122 .Company shares were Reiterated by Piper Jaffray on Apr 20, 2016 to “Neutral”, Firm has raised the Price Target to $ 106 from a previous price target of $105 .Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 122 from a previous price target of $114 .
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.